A Phase 1 interventional study of metformin and empagliflozin/metformin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-09.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and metformin extended release under fed conditions.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose empagliflozin/metformin
Drug: empagliflozin/metformin
single doses empagliflozin and metformin
Drug: metformin · Drug: empagliflozin
single dose of metformin given as tablets
Drug pages: Empagliflozin · Metformin
Single dose empagliflozin/metformin given as fixed-dose combination tablet
single dose of empagliflozin given as tablet
AUC0-tz of Empagliflozin in Plasma
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
AUC0-tz of Metformin in Plasma
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Cmax of Empagliflozin in Plasma
Maximum measured concentration of the empagliflozin in plasma
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
Cmax of Metformin in Plasma
Maximum measured concentration of the metformin in plasma
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
AUC0-infinity of Empagliflozin in Plasma
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
AUC0-infinity of Metformin in Plasma
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.
Time frame: -1:00 hour(h) before the drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 5:00h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration
| Milestone | Fed 10mg+1000mg Fixed Dose Combination (FDC)/Single (TR) | Fed 10mg+1000mg Single/FDC (RT) |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
| Milestone | Fed 10mg+1000mg Fixed Dose Combination (FDC)/Single (TR) | Fed 10mg+1000mg Single/FDC (RT) |
|---|---|---|
| Started | 15 | 15 |
| Completed | 15 | 15 |
| Not completed | 0 | 0 |
Area under the concentration-time curve of empagliflozin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
| nmol*h/L | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| AUC0-tz of Empagliflozin in Plasma | 2190 ± 18.1 | 2210 ± 16.3 |
Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz)
| ng*h/mL | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| AUC0-tz of Metformin in Plasma | 10800 ± 20.1 | 10700 ± 22.4 |
Maximum measured concentration of the empagliflozin in plasma
| nmol/L | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| Cmax of Empagliflozin in Plasma | 243 ± 23.1 | 245 ± 20.4 |
Maximum measured concentration of the metformin in plasma
| ng/mL | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| Cmax of Metformin in Plasma | 1170 ± 25.5 | 1080 ± 25.2 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.
| nmol*h/L | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| AUC0-infinity of Empagliflozin in Plasma | 2230 ± 18.0 | 2260 ± 16.3 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity.
| ng*h/mL | Fed 10mg+ 1000mg FDC (T) | Fed 10mg+1000mg Single (R) |
|---|---|---|
| AUC0-infinity of Metformin in Plasma | 11000 ± 20.8 | 10800 ± 22.7 |
Collected over From first drug administration until the end-of-trial examination (Up to 14 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fed 10mg+1000mg Single (R) | — | 0/30 (0%) | 9/30 (30%) |
| Fed 10mg+ 1000mg FDC (T) | — | 0/30 (0%) | 5/30 (16.7%) |
| Event | Fed 10mg+1000mg Single (R) | Fed 10mg+ 1000mg FDC (T) |
|---|---|---|
| HeadacheNervous system disorders | 5/30 | 4/30 |
| DiarrhoeaGastrointestinal disorders | 2/30 | 1/30 |
| NauseaGastrointestinal disorders | 2/30 | 0/30 |
Treated set (TS): The TS was made up of all randomised subjects who were documented to have received the trial medication.
| Age, Continuous(years) | Fed 10mg+1000mg FDC/Single (TR) | Fed 10mg+1000mg Single/FDC (RT) | Total |
|---|---|---|---|
| Mean | 33.5 ± 8.1 | 33.7 ± 10.1 | 33.6 ± 9.0 |
| Sex: Female, Male(Participants) | Fed 10mg+1000mg FDC/Single (TR) | Fed 10mg+1000mg Single/FDC (RT) | Total |
|---|---|---|---|
| Female | 6 | 8 | 14 |
| Male | 9 | 7 | 16 |
The record gives a start of Nov 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Empagliflozin · Metformin